Studio KIWI / Shutterstock

Company to Pursue Clinical Trials to Link Cannabis Gum to the Alleviation of IBS Symptoms

CanChew Plus CBD Gum is an all-natural, non-psychoactive product

Studio KIWI / Shutterstock

CBD has been known to have analgesic, anti-inflammatory, and anti-anxiety properties.

There have been studies linked to the consumption of low-carb rye bread to fewer irritable bowel syndrome (IBS) symptoms, but what about chewing gum? Results from a study conducted by AXIM Biotechnologies showed that the company’s cannabinoid (CBD) gum may alleviate symptoms from IBS and other gastrointestinal disorders.

Each piece of CanChew Gum contains 50 milligrams of CBD hemp oil and 10 milligrams of natural CBD, according to the Medical Marijuana Inc. website.

“We believe we can match or improve the bioavailability profile for CBD compared to other delivery systems such as smoking or oral intake,” George E. Anastassov, CEO of AXIM Biotech, said in a statement.

“We look forward to entering clinical trial and making available our cannabis-based medicine to patients suffering from IBS and other gastrointestinal disorders as soon as possible.”


Through a patient trial in which healthy volunteers chewed one piece of CanChew Plus Gum for 30 minutes, researchers found that a dose of 30 milligrams of CBD showed great potential to produce positive results during clinical trials.